MGV 354

Drug Profile

MGV 354

Alternative Names: MGV354

Latest Information Update: 12 Oct 2016

Price : $50

At a glance

  • Originator Alcon
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Glaucoma; Ocular hypertension

Most Recent Events

  • 01 Sep 2016 Alcon Research completes a phase-I/II clinical trial in Ocular hypertension and Glaucoma in USA (Ophthalmic) (NCT02743780)
  • 01 Mar 2016 Phase-I/II clinical trials in Glaucoma in USA (Ophthalmic) (NCT02743780)
  • 01 Mar 2016 Phase-I/II clinical trials in Ocular hypertension in USA (Ophthalmic) (NCT02743780)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top